(Q54543517)

31 May 2018

review article

1 reference

title

Preventing and treating biologic-associated opportunistic infections. (English)

1 reference

31 May 2018

author name string

Kevin L Winthrop

series ordinal

1

1 reference

31 May 2018

Tom Chiller

series ordinal

2

1 reference

31 May 2018

language of work or name

English

0 references

publication date

1 July 2009

1 reference

31 May 2018

Nature Reviews Rheumatology

published in

1 reference

31 May 2018

volume

5

1 reference

31 May 2018

page(s)

405-410

1 reference

31 May 2018

issue

7

1 reference

31 May 2018

https://scigraph.springernature.com/pub.10.1038/nrrheum.2009.105

exact match

0 references

cites work

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Coccidioidomycosis as a common cause of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Screening for tuberculosis infection prior to initiation of anti-TNF therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Tuberculosis associated with therapy against tumor necrosis factor alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.105

Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population

31 March 2020

1 reference

12 December 2020

Treatment of tuberculosis

1 reference

12 December 2020

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

1 reference

12 December 2020

Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS)

1 reference

12 December 2020

Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy

1 reference

12 December 2020

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

1 reference

12 December 2020

Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.105

1 reference

31 May 2018

Dimensions Publication ID

0 references

1 reference

31 May 2018